Trial · NCT03200717
Results by group106
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 106
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 19 Day 1 | 0.0 | Standard Deviation 2.76 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 19 Day 1 | 0.0 | Standard Deviation 2.76 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 22 Day 1 | -0.5 | Standard Deviation 3.27 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 22 Day 1 | -0.5 | Standard Deviation 3.27 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 25 Day 1 | 2.0 | Standard Deviation 2.31 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 25 Day 1 | 2.0 | Standard Deviation 2.31 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 31 Day 1 | 0.5 | Standard Deviation 0.71 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 31 Day 1 | 0.5 | Standard Deviation 0.71 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 34 Day 1 | 1.0 | Standard Deviation NA | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 34 Day 1 | 1.0 | Standard Deviation NA | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 37 Day 1 | 1.0 | Standard Deviation NA | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 37 Day 1 | 1 | Standard Deviation NA | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | End of Treatment | -0.6 | Standard Deviation 3.86 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 3rd Line | End of Treatment | -0.8 | Standard Deviation 6.00 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | End of Treatment | -0.6 | Standard Deviation 4.37 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 2nd Line | Cycle 2 Day 1 | 0.1 | Standard Deviation 16.44 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 3rd Line | Cycle 2 Day 1 | -1.9 | Standard Deviation 19.46 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | All Participants | Cycle 2 Day 1 | -0.4 | Standard Deviation 17.02 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 2nd Line | Cycle 3 Day 1 | -2.8 | Standard Deviation 14.35 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 3rd Line | Cycle 3 Day 1 | 3.6 | Standard Deviation 19.28 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03200717/results?page=3